Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey


Yozgat A. K. , LEBLEBİSATAN G., Akbayram S., Ozel S. C. , KARAKAŞ Z., ERDURAN E., ...More

TURKISH JOURNAL OF HEMATOLOGY, vol.37, no.3, pp.139-144, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 3
  • Publication Date: 2020
  • Doi Number: 10.4274/tjh.galenos.2020.2019.0380
  • Journal Name: TURKISH JOURNAL OF HEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.139-144
  • Keywords: Immune thrombocytopenia, Eltrombopag, Iron deficiency, QUALITY-OF-LIFE, DOUBLE-BLIND, THROMBOPOIETIN, ROMIPLOSTIM, ADULTS
  • Istanbul University Affiliated: Yes

Abstract

Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children.